Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.38 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.35 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 3/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28139935 | 0.98 | MME (0.39) | CYP2C19MMELMNACYP1A2SMN1; SMN2 | |
| SCHEMBL14865418 | 0.93 | PTGS1 (0.38) | CYP2C19MMELMNATSHRALKBH5 | |
| SCHEMBL2471005 | 0.88 | — | — | |
| SCHEMBL28194413 | 0.85 | LMNA (0.44) | LMNACYP1A2SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL16404744 | 0.82 | ALDH1A1 (0.39) | CYP2C19LMNASMN1; SMN2ALDH1A1SLC15A2 | |
| SCHEMBL8689460 | 0.81 | LMNA (0.39) | CYP2C19LMNACYP1A2SMN1; SMN2ALDH1A1 | |
| SCHEMBL8603006 | 0.80 | L3MBTL1 (0.38) | CYP2C19LMNACYP1A2SMN1; SMN2ALDH1A1 | |
| SCHEMBL14436663 | 0.79 | ALDH1A1 (0.41) | LMNASMN1; SMN2ALDH1A1SLC15A2 | |
| SCHEMBL10285150 | 0.78 | TDP1 (0.36) | LMNAFFAR3 | |
| SCHEMBL5537493 | 0.78 | GLA (0.38) | MMELMNATSHRALKBH5SUCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED) (IE) | 2015-11-12 | — | — | US | claimed |
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | claimed |
| US-20110105519-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | claimed |
| US-20080103155-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | SPROUT PHARMACEUTICALS, INC. | 2008-05-01 | — | — | US | claimed |
| EP-1418920-A4 | AS-NEEDED ADMINISTRATION OF ORALLY ACTIVE ANDROGENIC AGENTS TO ENHANCE FEMALE SEXUAL DESIRE AND RESPONSIVENESS | VIVUS INC (US) | 2006-10-04 | — | — | EP | claimed |
| US-20050245539-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | US | claimed |
| EP-1418920-A1 | AS-NEEDED ADMINISTRATION OF ORALLY ACTIVE ANDROGENIC AGENTS TO ENHANCE FEMALE SEXUAL DESIRE AND RESPONSIVENESS | Vivus, Inc. (US) | 2004-05-19 | — | — | EP | claimed |
| US-20040044080-A1 | Treatment of dyspareunia with topically administered nitroglycerin formulations | VIVUS, INC. | 2004-03-04 | — | — | US | claimed |
| WO-2003011300-A1 | AS-NEEDED ADMINISTRATION OF ORALLY ACTIVE ANDROGENIC AGENTS TO ENHANCE FEMALE SEXUAL DESIRE AND RESPONSIVENESS | VIVUS, INC. (US) | 2003-02-13 | — | — | WO | claimed |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED) (IE) | 2015-11-12 | — | — | US | disclosed |
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| EP-1806342-B1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVE | SHIONOGI & CO (JP) | 2013-04-17 | — | — | EP | disclosed |
| US-8367666-B2 | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. | 2012-08-16 | — | — | US | disclosed |
| WO-2003011301-A1 | AS-NEEDED ADMINISTRATION OF AN ANDROGENIC AGENT TO ENHANCE FEMALE SEXUAL DESIRE AND RESPONSIVENESS | VIVUS, INC. (US) | 2003-02-13 | — | — | WO | disclosed |
| US-20020013304-A1 | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness | VIVUS INC. | 2002-01-31 | — | — | US | disclosed |
| EP-0837845-B1 | HERPES RIBONUCLEOTIDE REDUCTASE INHIBITORS | BOEHRINGER INGELHEIM CA LTD (CA) | 2001-11-28 | — | — | EP | disclosed |
| EP-0837845-A1 | HERPES RIBONUCLEOTIDE REDUCTASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 1998-04-29 | — | — | EP | disclosed |
| US-5672586-A | Herpes ribonucleotide reductase inhibitors | BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH, INC. (CA) | 1997-09-30 | — | — | US | disclosed |
| WO-1997000855-A1 | HERPES RIBONUCLEOTIDE REDUCTASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD./BOEHRINGER INGELHEIM (CANADA) LTÉE. (CA) | 1997-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | CNR2, CNR1, HRH4 | CYP2C19 896/4885MME 2544/4885LMNA 4280/4885 |
| US-20080103155-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | FLNB, FLNA, FGB | CYP2C19 119/4885MME 2293/4885LMNA 1578/4885 |
| US-20020013304-A1 | As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness | SHBG, GNRHR, FSHR | CYP2C19 294/4885MME 1126/4885LMNA 4805/4885 |
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | CYP2C19 119/4885MME 2293/4885LMNA 1578/4885 |
| US-20110105519-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | CYP2C19 119/4885MME 2293/4885LMNA 1578/4885 |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | CYP2C19 119/4885MME 2293/4885LMNA 1578/4885 |
| US-20040044080-A1 | Treatment of dyspareunia with topically administered nitroglycerin formulations | PDE12, PDE3A, PDE2A | CYP2C19 280/4885MME 1290/4885LMNA 3409/4885 |
| US-20050245539-A1 | Pharmaceutical compositions for the treatment of sexual disorders II | FLNB, FLNA, FGB | CYP2C19 119/4885MME 2293/4885LMNA 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.